The complaint alleges that ADMA Biologics and several of its officers orchestrated a scheme to inflate financial results. Specifically, the lawsuit contends the company engaged in undisclosed related-party transactions and utilized channel stuffing to artificially boost revenue figures. Plaintiffs argue that these actions, combined with a lack of adequate internal controls, rendered the company's public statements regarding its operations materially false or misleading throughout the specified class period.

Investors who suffered losses during this window have until August 10, 2026, to apply to the court to serve as lead plaintiff. While the firm operates on a contingency fee basis, meaning legal costs are only recovered from the final settlement if successful, shareholders are not required to lead the case to participate in a potential recovery. Those interested in reviewing the full complaint or discussing the litigation can contact Peretz Bronstein or Nathan Miller at 917-590-0911.